GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sotera Health Co (NAS:SHC) » Definitions » EBIT

SHC (Sotera Health Co) EBIT : $301 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sotera Health Co EBIT?

Sotera Health Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $84 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $301 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sotera Health Co's annualized ROC % for the quarter that ended in Sep. 2024 was 4.72%. Sotera Health Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 31.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sotera Health Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 5.15%.


Sotera Health Co EBIT Historical Data

The historical data trend for Sotera Health Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sotera Health Co EBIT Chart

Sotera Health Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 156.81 176.40 249.91 -162.97 248.91

Sotera Health Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.10 108.32 52.79 55.53 84.33

Competitive Comparison of Sotera Health Co's EBIT

For the Diagnostics & Research subindustry, Sotera Health Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sotera Health Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's EV-to-EBIT falls into.



Sotera Health Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $301 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sotera Health Co  (NAS:SHC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sotera Health Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=322.028 * ( 1 - 60.24% )/( (2707.014 + 2715.268)/ 2 )
=128.0383328/2711.141
=4.72 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3057.818 - 104.72 - ( 246.084 - max(0, 169.633 - 497.677+246.084))
=2707.014

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3148.737 - 126.731 - ( 306.738 - max(0, 195.537 - 563.613+306.738))
=2715.268

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sotera Health Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=337.304/( ( (1018.886 + max(63.743, 0)) + (1055.294 + max(37.75, 0)) )/ 2 )
=337.304/( ( 1082.629 + 1093.044 )/ 2 )
=337.304/1087.8365
=31.01 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(123.659 + 57.872 + 33.151) - (104.72 + 12.989 + 33.23)
=63.743

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(130.121 + 53.647 + 26.615) - (126.731 + 10.653 + 35.249)
=37.75

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sotera Health Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=300.964/5846.271
=5.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sotera Health Co EBIT Related Terms

Thank you for viewing the detailed overview of Sotera Health Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sotera Health Co Business Description

Traded in Other Exchanges
N/A
Address
9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Executives
Warburg Pincus & Co. director, 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Gtcr Fund Xi/a Lp director, 10 percent owner 300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Ann R. Klee director 30 ISABELLA ST., PITTSBURGH PA 15212
Michael P Rutz officer: President of Sterigenics 8755 WEST HIGGINS ROAD, SUITE 500, CHICAGO IL 60631
Petras Michael B. Jr. director, officer: Chairman & CEO 9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS OH 44147
Jonathan M. Lyons officer: Sr. Vice President, CFO 9100 SOUTH HILLS BLVD., SUITE 300, BROADVIEW HEIGHTS OH 44147
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Robert Brown Knauss director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Alexander Dimitrief officer: SVP, General Counsel and Sec. GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Michael F Biehl officer: Interim CFO 5885 LANDBROOK DRIVE SUITE 205, CLEVELAND OH 44124
Terry Hammons officer: SVP, GC and Secretary C/O SIMPSON MANUFACTURING CO., INC., 5956 W LAS POSITAS BLVD, PLEASANTON CA 94588
Wp Xi Partners, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, 450 LEXINGTON AVENUE NY 10017
Matthew J Klaben officer: SVP, GC and Secretary ONE INFINITY CORPORATE CENTRE DRIVE, SUITE 300, GARFIELD HEIGHTS OH 44125
Stephanie Geveda director 450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Sean Laurence Cunningham director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654